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USE OF MEDIA TO IMPROVE HUMAN PAPILLOMA VIRUS (HPV) VACCINE
ACCEPTABILITY
Pavithra Venkat, Ella Chapman, Emily Ko, and Elizabeth Garner. Department of Obstetrics and
Gynecology, Brigham and Women’s Hospital, Boston, MA. (Sponsored by Jessica Illuzzi,
Department of Obstetrics and Gynecology, Yale University School of Medicine).
Our objective was to determine if using a video educational tool can influence (1) individual
vaccine acceptability (2) parental acceptability, (3) parental views on vaccine mandates, and (4)
age of vaccination accepted for the Human Papilloma Virus (HPV) vaccine. We conducted a
cross-sectional study using bilingual surveys distributed at Brigham and Women’s and
Massachusetts General Hospital clinics and at the Coalition of Boston Public Health Association
from January to March 2007. An initial 32-question survey addressing HPV knowledge, beliefs
and vaccine acceptability was completed, followed by an eight-minute video about HPV and the
vaccine. An additional 11-question post assessment was then completed. Five questions were
extracted from both the pre/post questionnaires to evaluate HPV vaccine acceptability. Out of 256
subjects, 186 (73%) completed the video intervention and pre/post surveys. Of the 186, 66.6%
(124) of subjects said they would vaccinate themselves. Individual acceptability increased after
the video to 78% (p=.0014). An additional 55.8 % (102/186) of subjects supported making the
HPV vaccine required for all children, with 51.1% (95/186) supporting vaccination if it were
given at school and 66.7% (124/186) supporting child vaccination if it were free. After the video,
this increased to 72.6% (p<.0001), 65.1% (p<.0001) and 86.6% (p<.0001) respectively.
Initially, 56.5% (105/186) of subjects would vaccinate their child only if the child were older than
15 years of age; post-intervention, 82.3% of subjects accepted vaccination starting at age 9 and up
(p<.0001). Secondary analysis revealed that Hispanic, Blacks and those with combined income
less than $50,000 were more likely to not initially accept HPV vaccine for their children but
showed high rates of acceptability after intervention. People’s perception that vaccination will
promote sex amongst the young was significant but did not affect overall acceptability. In
conclusion, using multi-media as a way to increase knowledge significantly increased individual
acceptability, parental acceptability, and age of acceptance of the HPV vaccine.
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I. Introduction
The approval of the quadrivalent Human Papilloma virus (HPV) vaccine
(Gardasil© - HPV 6, 11, 16, 18) in June 2006 by the US Food and Drug Administration
represented a landmark step in the prevention of cervical cancer. Persistent infection with
certain subtypes of HPV has long been known to be associated with both cervical cancer
and genital warts. A reduction in the acquisition of HPV could significantly lower the
incidence of future high grade cervical lesions and reduce condylomatous disease. (1, 2)
In order to achieve a reduction in population prevalence of HPV, full series vaccination
of girls aged 11 to 26 is needed. Public health interventions that focus on understanding
barriers and improving acceptability towards vaccination will be important in helping to
achieve target levels of vaccination.
A. Incidence, Prevalence & Risk Factors
HPV is the most common sexually transmitted infection in the United States. Data
from the National Health and Nutrition Examination Survey (NHANES) 2003-2004
suggests the prevalence of HPV infection to be as high as 26.8% (95% CI, 23.3%-30.9%)
in a representative sample of 1,921 American women aged 14-59. (3) The NHANES
group found a combined prevalence of the four vaccine types targeted by the quadrivalent
vaccine (6, 11, 16 &18) of 3.4% and a combined prevalence of oncogenic subtypes 16
&18 of approximately 2%. Most notably, the study found that prevalence rose between
the ages of 14-24 and then gradually declined until age 59, suggesting that younger
women are at higher risk for acquiring HPV. [Figure 1]
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Figure 1. From Dunne, et al (3)

A second study, the National Longitudinal Study of Adolescent Health
(ADHEALTH), looked specifically at US adolescents aged 18 to 25 and found a
combined prevalence in this group of 26.9%. The ADHEALTH study identified a
significantly lower prevalence in youth than the 49.3% prevalence of HPV infection in
the 20 to 24 year old subgroup of the NHANES study. In their JAMA editorial, authors
Weller and Stanberry (4)remark on this discrepancy (while noting the limitations in exact
comparison between the two studies) and suggest that the method of viral detection –
using urine samples in ADHEALTH vs. cervico-vaginal swabs in NHANES – could
account for an underestimation of prevalence amongst younger women in ADHEALTH.

3
Independent risk factors for HPV acquisition in the NHANES study included age,
marital status, and increasing number of lifetime and recent sexual partners. Of note,
HPV prevalence in Black women was 39.2% versus 24.2% in non-Hispanic Whites and
24.3% in Mexican American women (p<0.001). (3) However, while race was a risk
factor for HPV in bivariate analysis, this did not prove the case in the multivariate model.
Further work on the NHANES data by Kahn et al (5) demonstrated that women living
below the poverty line were more likely to be infected with a high-risk subtype of HPV
than those living three or more times above it. One possible conclusion from this data is
that socioeconomic status or other confounding factors and not race could account for the
above differences in prevalence in Black women. In multivariate analyses of both studies,
educational level was not associated either positively or negatively with HPV infection.
Given the natural history of HPV – exposure followed by viral clearance in the
majority of women– it is logical to assume that a peak in infection would occur in women
around the age of sexual debut and first exposure to the virus. It is also important to note
that any study of prevalence will count a large number of infections that will clear on
their own; only a small percentage of these persist, and it is these persistent infections
that lead to pre-cancerous changes.
B. Establishing the connection between HPV and Cervical Cancer
Papillomaviruses have evolved to survive in the various transformation zones of
the body and different subtypes have been linked to oropharyngeal, cervical, and
anogenital cancers. The majority of cervical cancers arise in an area of the cervix called
the transformation zone, so named because of the junction of stratified squamous
epithelium of the ectocervix with the columnar epithelium of the endocervix. (6)
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HPV types 16 and 18 are the subtypes most commonly linked to cervical cancer in the
United States and the developed world. Together they are responsible for about 70% of
cervical cancer and approximately 50% of cervical intraepithelial neoplasia (CIN) grade
3. Infection with two other subtypes of HPV, 6 and 11, accounts for 90% of genital warts.
HPV subtype 16 is predominantly associated with the more common squamous cell
cancers, while HPV type 18 has been strongly linked to adenocarcinomas arising from
columnar glandular cells. Recent data suggests that cervical adenocarcinoma incidence
has not decreased at the same rate as squamous cell carcinomas; this may in part be due
to the fact that these cancers are located in the more internal columnar cells of the cervix
and thus more often escape detection during PAP smears. Adenocarcinomas are also
attributed with different risk factors and show different patterns of progression than
squamous cell carcinomas.(7)
Transmission of HPV occurs through micro-tears in the mucosa, most commonly
during sexual intercourse. Research suggests that the viral particles can travel from the
vaginal introitus to reach cervical cells, suggesting that penetrative sexual intercourse is
not necessary for transmission. Interestingly, some additional data suggests that male
circumcision may reduce transmission of HPV; a proposed theory suggests keratinized
penile epithelium may impede mucosal transfer. (6)
The HPV viral genome consists of only eight genes. Initial studies suggest that the
mechanism of viral action for HPV involves two specific proteins, E6 and E7, which are
encoded by the HPV genome (see Figure 2). E6 and E7 are onco-proteins with multiple
cellular targets, most notably the p53 and retinoblastoma tumor suppression proteins
(pRB) respectively. Inhibition of p53 by E6 leads to blockage of apoptosis, and inhibition
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of pRB by E7 leads to cell cycle arrest. These proteins are expressed at low levels during
infection. At a point during viral persistence deregulation occurs, leading to overexpression of the proteins in full thickness epithelium and subsequent changes in the cell
cycle that lead to the development of pre-cancerous changes. (8)
Figure 2 Adapted from Schiffman, et al. (6)

C. Progression to Cancer
Approximately 30% of women newly infected with HPV show some
abnormalities in cervical cytology. The majority of women will clear the infection within
2 years. However, in a subset of approximately 10% of these women, viral persistence
occurs with a clone of infected cells that eventually progress to pre-cancer. Abnormalities
detected on Pap that persist for greater than one year are therefore most concerning for
pre-cancerous change. Of the HPV subtypes, HPV 16 is the most oncogenic, with a 40%

6
absolute risk of progression to pre-cancer if infected persistently for 3-5 years. Of note
smoking, multiparity, and long term use of oral contraceptives (OCPs) can double to
triple the rate of progression to pre-cancer. (6) Women with HIV also show increased
viral persistence and longer time to clearance of HPV infections and may be at increased
risk for progression to pre-cancer.
Abnormalities of the cervix are characterized by either cytological diagnosis
(typically by a PAP smear) or a histological diagnosis. The cytological classification
scheme includes the following designations: LSIL (Low Grade Squamous Intraepithelial
Neoplasia), HSIL (High Grade Intraepithelial Neoplasia), ASC-US (Atypical Squamous
Cells of Undetermined Significance) and ASC-H (Atypical Squamous Cells cannot
exclude High Grade Lesion). The histopathological classification scheme includes the
diagnoses of cervical intraepithelial neoplasia (CIN) Grades 1 through 3. It is important
to realize that though a large number of pre-cancers are detected, not all of these will
progress to invasive cancer. For further explanation of the significance, rates of
progression, and management of lesions based on the above schemata, please refer to the
following tables.
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Table 1 Histological Classification and Management of Cervical Intra-epithelial Neoplasia1,2
CIN 3
Severe
Dysplasia
or
Dyskaryosis
Carcinoma
in Situ
CIN 2

CIN 1

•

Pre-Cancer

•

•

Equivocal – can be
produced by noncarcinogenic HPV
types. Data
suggests 43-48%
regress if untreated,
22% progress to
CIN 3, 5% to
invasive cancer
Insensitive
Histopathological
sign of HPV
Infection, one study
suggests 51%
regress.

•
•

•
•
•

32-47%
spontaneous
regression
12-36% to
invasive cancer
43-48%
regression
22% progression
to CIN 3
5% progression
to invasive CA

47% regression
21% progression
to high grade
0.15% to
invasive CA

Excision or Ablation of Tzone
Then:
• PAP or PAP+Colpo
@4-6 mos (3 – then go
to annual)
• Or HPV @ 6mos (if –
go to annual PAP)
• If ASC, SIL, or HPV+
then repeat colposcopy

•

•

•

Serial pap at 6 & 12
mos (2 – smears,
return to annual, ASC
or grtr Æcolpo)
Or HPV test in 12 mos
with referral to colpo if
+ (if – go to annual
Pap)
If post-menopausal or if
fertility irrelevant, can
go to excision.

Table 2 Cytological Classification and Management of Pre-Cancerous Changes 1,2
LSIL

HSIL

Roughly
corresponds to
CIN 1, 15% risk
of underlying
CIN 2,3.

•
•

Roughly
corresponds to
CIN 2,3 (7075% risk)

•
•

•

1

47% regress
21% progress to high
grade lesion
0.15% to invasive
cancer @ 24 mos
35 % regress
1.4% to invasive CA
@24 mos

Referral to Colposcopy +/ECC
Post Menopausal Women &
Adolescents:
• Serial cytology in 6 &
12 mos
• or HPV in 12 mos.
Referral to Colposcopy +/ECC
• If Colpo negative still
recommend excision
Adolescents
• can have repeat

Information compiled from Up to Date, American Society for Colposcopy & Cervical Pathology
(ASCCP) Consensus Guidelines, and American College of Obstetricians and Gynecologists Guidelines.
Progression rates from (38, 39). Note: Colpo = Colposcopy. PAP = Papanicolou test. ECC= EndoCervical Curretage
2

Management may differ in HIV patients.
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colpo+ECC at 6 mos1 yr
ASC –
US
ASC – H

Atypical
Squamous
Cells of
Undetermined
Significance

•
•
•

68 % regression
7 % progression to high
grade lesion
0.25% invasive CA @
24 mos

Atypical
Squamous
Cells Cannot
Exclude High
Grade Lesion

The average age of detection of those with viral persistence and precancerous
changes is 10 years after sexual debut, which in the Untied States means peak detection
of pre-cancerous changes at ages 25 to 35 years of age. The peak age range for detection
of invasive cancers is subsequently age 35 to 55. It is important to note that the time
between acquisition of HPV infection and the development of cancer can exceed 20
years.
HPV genetic testing is now available and is being utilized alongside PAP smears
for detection and management of lesions. Screening with the HPV test can catch precancerous changes often earlier than either cytology or colposcopy can, but also leads to
the identification of a large number of changes related to recent infections which may
clear on their own with time. Current American Cancer Society and American College of
Obstetricians and Gynecologists (ACOG) recommendations suggest utilization of the
HPV test as an adjunct to Pap screening in women over 30 (with a negative test leading
to greater intervals between Pap testing) or in triage of women with equivocal ASC-US
lesions on Pap smear.
There is still a great deal to be learned about the pathway of progression to
cervical cancer. For example, research is unclear whether women do truly clear HPV
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infections, or whether the virus can persist in a latent stage. The preponderance of HPV
positivity in HIV patients may suggest that a latent stage is reactivated when the immune
system is weakened. Studies must also substitute CIN II and II as surrogate markers for
cervical cancer, since the standard of care requires treatment of lesions before they
progress to cancer.
D. Epidemiology of Cervical Cancer
The American Cancer Society estimates that 11,150 cases of cervical cancer are
diagnosed each year in the United States. Non-invasive cervical cancer (carcinoma in
situ) is approximately 4 times more common than invasive cancer.(9) It is estimated that
in 2007 about 3,670 women will die from cervical cancer. Death rates from cervical
cancer have declined significantly in the last forty years as a result of increased use of the
Papanicolou screening test and experts predict that they will continue to decline at a rate
of approximately 4 % a year. Cervical cancer tends to disproportionately affect the
worlds poorest regions; over 80% of cases occur in developing nations in Latin America,
Sub-Saharan Africa, and India.(10)
Cervical cancer is clinically staged with the FIGO (International Federation of
Gynecology and Obstetrics) System of Staging [Table 4]. This system classifies the
disease in stages 0 through IV as determined by clinical spread of disease. Clinical spread
is determined by a combination of physical examination, colposcopy, histopathology (on
biopsy or conization), radiography (chest x-ray; CT, MRI, and PET to determine lymph
node involvement), and endoscopy (cystoscopy or sigmoidoscopy). One randomized
controlled trial evaluated surgical staging versus clinical staging and found no
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difference(11); however, other evidence suggests improved results with surgical
staging(12).
In the future FIGO recommendations may be modified to incorporate surgical
staging; however, at present, especially given the preponderance of cervical cancer in
developing countries without access to technology, the FIGO system remains clinically
based. A rough guide to staging is as follows: Stage I (subdivided into IA1,IA2,IB1,IB2)
corresponds to lesions confined to the cervix, Stage II (IIa,IIb) with spread to the vagina
and then pelvis but not the lower 1/3 of the vagina or the pelvic side wall, Stage III
(IIIa,IIIb) with spread into the lower third of the vagina or the pelvic wall, and Stage IV
with spread to other organs.
The five year survival rate for the earliest stages (I-II) of invasive cervical cancer is 8095% and 60% for Stage III.(10) The combined overall survival rate for all stages is 76%.
(9) Treatment options typically involve some combination of surgery, chemotherapy, and
radiation therapy [Table 3].
With this relatively high survival rate (in developed countries where access to
surgery and radiation therapy is possible), the question arises as to the cost effectiveness
and need for a mandatory vaccination. However, as discussed in the following sections,
the vaccine may also have great cost-saving potential in terms of the millions of dollars
spent on screening and treatment of abnormal cervical lesions in the United States.
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Table 3 International Federation of Obstetrics and Gynecology (FIGO) Clinical Staging
and Management of Cervical Cancer 3
Stage Description
General Management
Invasive carcinoma, confined to cervix, diagnosed
• Hysterectomy or
IA1
only by microscopy. Stromal
invasion ≤3 mm in depth and ≤7mmin horizontal
spread

IA2

IB1
IB2
IIA

Invasive carcinoma, confined to cervix, diagnosed
only by microscopy. Stromal
invasion >3 mm and ≤5 mm in depth and ≤7 mm in
horizontal spread
Invasive carcinoma, confined to cervix, microscopic
lesion >IA2 or clinically visible lesion ≤4 cm in
greatest dimension
Invasive carcinoma, confined to cervix, clinically
visible lesion >4 cm in greatest dimension
Tumor extension beyond cervix to vagina but not to
lower third of vagina. No parametrial invasion

•

•

•
•

•

IIB

IIIA
IIIB
IVA
IVB

3

Tumor extension beyond cervix. Parametrial invasion
but not to pelvic side wall and not to lower
Third of vagina
Tumor extension to lower third of vagina but not to
pelvic side wall
Tumor extension to pelvic side wall or causing
hydronephrosis or non-functioning kidney
Tumor invasion into bladder or rectum
Distant metastasis

Adapted from (10)

•

•

Conization
Possible Radical
Surgery or Radiation if
Lymphovascular
Involvement
Radical
Hysterectomy for
ovarian preservation
(+adjuvant chemoradiotherapy if risk
factors) or
Radiotherapy
(outcomes similar)
Radical
Trachelectomy +
Pelvic
Lymphadenectomy
for preservation of
fertility
Possible future for
Sentinel Node
Biopsy = Straight to
radio-chemotherapy
without radical surgery
Chemo-Radiotherapy
(platinum based) then
possible surgery

Palliative
Chemotherapy
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E. Development of HPV Vaccines
There are currently two HPV Vaccines developed for primary vaccination,
Gardasil (© Merck) and Cervarix (© GlaxoSmithKline). While both target the oncogenic
HPV Subtypes 16 and 18, Gardasil also offers additional protection from HPV 6 and 11,
subtypes which are common causes of genital warts. Both vaccines consist of virus-likeparticles (VLPs), in this case the recombinant L1 protein of HPV expressed in yeast and
self-assembled into non-infectious capsids. Intramuscular injection of the vaccine leads to
production of high titers of neutralizing antibody, which are subsequently secreted into
the vagina and cervix where they target HPV.
As of 2007 four major randomized, double-blind, placebo controlled studies have
evaluated the efficacy of the HPV vaccines: one phase II study of the monovalent HPV
16 vaccine in 16-23 year olds (protocol 005), one phase II study of the quadrivalent
vaccine in 16-23 year olds (protocol 007), and two phase III studies (protocols 013 and
015) of the quadrivalent vaccine in 16-23 and 16-26 year olds respectively. (13-15)The
two phase II studies evaluated the efficacy of the vaccine on persistent infection with
HPV, and the phase III studies took this one step further and looked at the effect on
clinical lesions (CIN, Vaginal Intraepithelial Neoplasia (VIN), genital warts). Of note
these clinical lesions must serve as surrogate endpoints for the effect of the vaccine on
cervical cancer since current standards of care require pre-cancerous lesions to be treated
before progression to cancer can be verified.
Table 4 CDC Recommendations of the Advisory Committee on Immunization Practice
(ACIP): A Summary of Vaccine Efficacy Studies (16)
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The vaccines were found to be highly effective. In fact, the combined efficacy of
the trials against HPV 16 or 18 related CIN 2/3 or Adenocarcinoma in Situ (AIS) was
100% (CI 92.9-100.0). The efficacy against CIN 1 as well as the above was 95.2% (87.298.7), and the combined efficacy against subtype related genital warts was 98.9% (CI
93.7-100.0). (16)
The efficacy in the phase III trials was detected up to four years after initial
vaccination; studies are ongoing to determine longer term efficacy. One phase II study
showed a decline in antibody levels at 24 months followed by a plateau but maintained
that antibody levels were still much higher than placebo or levels associated with
previous infection. Another Phase II trial aims to follow Nordic women for at least 14
years with serologic testing for HPV at 5 and 10 years after vaccination. (16) Critics of
compulsory vaccination point to the limitation of the time of follow up of current studies;
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it is unclear as of now how long immunity persists and whether women may require a
booster shot down the line.
In addition the data on the effect of vaccination on women already infected with
one or more types of HPV is limited; initial data suggests that in women who are already
HPV subtype DNA positive at baseline, the vaccine is significantly less effective (CIN
preventive efficacies ranging from 39-47%). However, studies of antibody protection do
show a boost after administration of the vaccine in women who already have natural
immunity to a sub-type of HPV infection. (14)
F. Vaccination Guidelines
Gardasil is currently the only vaccine approved in the United States and has been
approved for ages 9-26. Recommendations by the CDC Advisory Committee on
Immunization Practice (ACIP) are for vaccination of girls 11 to 12 years of age, although
the vaccine has been approved for ages 9 and above. (16)Catch up vaccination for girls
aged 13 to 26 is recommended; however, the vaccine is most effective if given before
sexual exposure and will have limited to no benefit in women who already have one or
more of the subtypes of HPV found in the vaccine.
The vaccine is given in three doses at with the second and third doses
administered 2 and 6 months after the first respectively. It has been approved for
simultaneous administration with age-related Meningococcal vaccine and the Tdap
booster. At this time immunogenicity and safety data is available on vaccination of men,
but trials looking at efficacy are pending. The vaccine is not recommended for pregnant
women, and has been classified as Category B in pregnancy based on animal studies.
G. Impacts of Vaccination
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Estimates suggest that the prevention and treatment of anogenital warts and HPV
related disease in the United States results in $4 billion or more in direct costs each year.
Of this, approximately $200 million is attributable to genital warts, $300-400 million to
invasive cervical cancer, and the rest to routine cervical cancer screening. (16)
Several models have been developed to evaluate both the public health and monetary
impact of the HPV Vaccine in the United States. Goldie et al utilized a Markov model; a
mathematical model that hypothetically follows 100,000 adolescent girls through their
lifetime and estimates probabilities of transitioning between several health states (i.e. not
infected, infected with one or more subtypes of HPV, exhibiting degrees of cytologic
change on Pap smear, degrees of invasive cancer, etc) to determine endpoints such as
quality-adjusted life years (QALY) gained and total cost. This type of modeling requires
certain assumptions; in the case of Goldie et al, assumptions were made of 90% vaccine
efficacy and achievement of full series vaccination in all girls at age 12. (17)
Goldie et al estimated an absolute lifetime risk of cervical cancer of 3.64% in the
absence of any screening and a 0.86% risk with current screening practices. They were
then able to show that full series vaccination of girls at 12 years of age against HPV
subtypes 16 and 18 would lead to a decrease in the absolute lifetime risk of cervical
cancer to 0.30-0.47%. The incremental cost-effectiveness of this vaccine (above current
screening practices) would range from $20,600 (with 100% vaccine efficacy) to $33,700
(70% vaccine efficacy) per QALY. Other studies have used dynamic transmission models
which incorporate the benefits of herd immunity, finding a 75% reduction in cervical
cancer incidence at a much lower cost of $3,000 per QALY. (18). All cost effectiveness
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assays are sensitive to variables such as duration of vaccine coverage, vaccine cost, and
frequency of cervical cancer screening.
Further comparisons by Goldie et al of different combinations of prevention
strategies (screening plus vaccination, screening alone, etc) were made, and the study
determined the most effective strategy (with a cost effectiveness ration of less than
$60,000 per QALY) to be vaccination at 12 years of age accompanied by triennial
cytologic screening beginning at 25 years. This strategy would reduce the lifetime risk of
cervical cancer by 94% compared to no screening; by comparison, vaccination with
annual screening starting at age 18 years would cost more than $3.5 million per QALY.
The study reports that the proposed strategy of vaccination at 12 years with
triennial pap screening is more effective than current screening practices and represents
the best combination of cost and benefits. Most notably, it is a combination of prevention
of costly high grade lesions and a lessening of the frequency of Pap smears required after
vaccination that contributes to its cost-effectiveness in the US. This analysis of cost per
QALY would obviously differ greatly in nations where screening practices are much less
widespread and presentation of invasive cancers more common.
Even within the United States, a reduction in HPV acquisition would have a
particularly strong impact on the low income and minority women who tend to be
disproportionately affected by cervical cancer, improving their quality adjusted life
expectancy years in a cost-effective manner. (19) According to data from the National
Cancer Institute SEER Statistics from 2000-2004, the rate of cervical cancer is
considerably high in Hispanic (13.8 per 100,000 women) and Black (11.4 per 100,000)
women than in Caucasian women (8.5 per 100,000). Black and Hispanic women were
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also more likely to die from cervical cancer than white women (mortality rates of 4.9 and
3.3 per 100,000 respectively). (20, 20) One explanation for racial disparities in incidence
is differences in access to screening. A program that incorporates primary prevention
through vaccination could therefore help to eliminate some of the racial disparities in
cervical cancer in the United States. (16)
H. Current Knowledge of Vaccine Acceptability and Barriers to Vaccination
Despite the compelling data on the vaccine’s efficacy and cost-effectiveness,
formidable barriers to its universal adoption exist. A New England Healthcare Institute
expert panel estimate suggests that the full series adoption rate amongst the initial target
population will be only 15% in the first year.(19) Cited barriers to adoption include lack
of knowledge about HPV, resistance to vaccinating minors, concern over school or
government mandates for vaccination, and worries about vaccine safety.[5-9] (21)(21-25)
An understanding of the role that education can play in influencing public acceptability
towards vaccination is thus critical to ensure that the vaccine reaches its maximum public
health potential.
To date the literature has yielded mixed results regarding the effects of education
on public acceptability of vaccination. Lascano-Ponce et al showed that following being
given information about HPV, a high percentage (83.6%) of Mexican women indicated
they would allow their daughters participate in a trial of the HPV Vaccine; however, preeducation acceptance was not reported. (26)
Within the US, Dempsey et al randomized an educational sheet to half of 1600
parents of 8 to 12 year olds who were mailed a survey about HPV vaccination. Analysis
of the 840 returned surveys found no significant differences in acceptability between
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those given the educational sheet and the control group. (27) In comparison Davis et al
did find a difference in acceptability post education. Parents were given an information
sheet addressing prevalence of infection, mode of transmission, and severity of sequelae.
After reading the materials, 37 % of parents of 10-15 year olds who were initially
opposed to the vaccine changed their mind and 65% of undecided parents became in
favor of vaccination.(28) Other qualitative studies have assessed general parental
attitudes towards vaccination (especially towards vaccination for a sexually transmitted
infection) and have found that in general parents are accepting of health
recommendations that will protect their children, regardless of the mode of transmission
of infection.(29, 30) Of note the majority of these studies were done prior to vaccine
availability and the concurrent increase in media coverage both for and against the
vaccine.
I. Vaccine Mandates and Public Opinion
Over 20 states in the US are currently considering laws to make HPV vaccination
mandatory for pre-teen girls. The law governs that individual states and not the federal
government have the authority to mandate vaccines. This has led to legislative debate on
the individual state level involving both liberal and religious conservative groups. A
storm of debate was initiated in Texas after the Republican Governor issued a mandate
for vaccination of girls entering the 6th grade. The legality of this mandate is now being
challenged by the state’s attorney general on the basis that it infringes upon parental
rights and may promote promiscuity. Legislation has already been defeated in
Mississippi, West Virginia, Kentucky and New Mexico. (31-34) Though the New Mexico
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legislation passed through the state House and Senates, it was ultimately vetoed by the
state’s Democratic governor
Prior reports addressing school mandates have been in the form of editorials and
polls. The National Poll on Children’s Health included in 48 states reported that 45% of
parents support school mandates for HPV vaccination as compared to 68% parental
support for a new teen vaccine that prevents tetanus, diphtheria and whooping cough
(Tdap). (35) Opponents for HPV vaccination cite state legislation as an unwarranted
intrusion on individual and parental rights. Proponents of mandating vaccination suggest
that an “opt out” clause (by which parents can choose to opt out of mandated vaccination
on religious or personal grounds) preserves parental autonomy while also promoting
widespread achievement of public health goals.
Various groups have cited concerns that the vaccine would encourage sexual
promiscuity amongst teens. Implicit in this is the idea that acknowledging teen sexuality
is to promote it. Furthermore, teens are far more likely to react to the more immediate
threats of AIDS or pregnancy in determining sexual action than to the remote risk of
cervical cancer from HPV and the fact that they are protected from it.(32)
Opponents to mandating vaccination suggest abstinence as an easy and safe
alternative. Data from the CDC shows that while only 13% of American girls are
sexually experienced at 15, by 17 this number climbs to 43%, and by 19 years of age to
70%. Studies have also shown that abstinence only education does not necessarily delay
or decrease the onset of sexual activity amongst teens.
Other arguments against vaccination cite the limited data on the longevity of
protection offered by the vaccine and its unknown long term effects. It has been reported
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that in many cases pediatricians have restricted themselves to educating and counseling
objecting families, since the risks posed by going unvaccinated are not considered a
danger to the health of communities given the mode of transmission. (32, 35)

II. Objective
It was our objective to determine whether use of a multimedia educational tool,
given the current climate surrounding the HPV vaccine, could affect the following: 1)
Individual vaccine acceptability 2) Parental vaccine acceptability and 3) Parental views
on vaccine mandates, school vaccination, and acceptable age for vaccination. A
secondary objective included identifying whether acceptance post education varied
amongst ethnic, socioeconomic, and religious/cultural subgroups.

III. Methods
Surveys for this cross-sectional, voluntary study were distributed to 256 women
between the ages of 18 and 60 during a period extending from January to March 2007.
Institutional approval was obtained from the Partners Institutional Review Board
committee. Subjects were recruited from the following sites: Brigham and Women’s
Obstetrics and General Gynecology Clinics, Pap Smear Evaluation Clinics at both
Brigham and Women’s and Massachusetts General Hospitals, and the REACH 2010
Coalition of the Boston Public Health Association.
Those recruited from clinic sites were approached while in the waiting area by a
bilingual research team member and asked to participate. All study materials were
available in both English and Spanish. Subjects who agreed to participate (258)
completed a 32-question initial assessment addressing general knowledge and beliefs
about HPV as well as a section on demographic information and sections addressing both
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parental and individual vaccine acceptability. These subjects were then asked to watch an
eight-minute video about HPV and the vaccine. The educational video used was
produced by the research team and consists of 3 segments addressing: 1) facts about HPV
and transmission 2) prevalence and incidence of HPV and 3) information about the
vaccine. [Table 5]. Those that watched the video (186 subjects) then completed an
additional 11-question post-survey assessment.

Table 5 Educational Video Content
Section I
What is HPV?
How is HPV transmitted?
How does HPV lead to cervical cancer & genital warts?
What can you do about HPV?
Section II
How common is HPV?
How and when are youth affected by HPV?
What are risk factors for acquiring HPV?
Section III
What is a vaccine?
What does the HPV vaccine protect against?
What are the side effects of the vaccine?
How is it given?
Who can get it?

Five questions were extracted from pre and post questionnaires to evaluate HPV
vaccine acceptability. These questions would address whether participants would 1)selfvaccinate 2) vaccinate their children 3)support making the vaccine mandatory for all
children 4)vaccinate their children if the vaccine were free and lastly subjects were asked
to identify 5)the youngest age at which they would vaccinate their children. Primary
statistical analysis of the data was performed using the McNemar test to evaluate the
effectiveness of the video intervention. Secondary analyses were performed using the Chi
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squared and Fisher’s Exact tests to determine whether specific factors played a role in
acceptability.

IV. Results
Of the 256 subjects that participated in the study, 73% (n=186) completed the
video intervention and surveys. Eighty percent (n=150) of the subjects had heard of
HPV, while 65% (n=120) of subjects knew the HPV vaccine was available prior to
viewing the video. The demographics of the study population are listed in Table 1. The
majority of study participants identified as Black or Hispanic (55%), with 27 % selfidentifying as Caucasian.
Participants were primarily single (43%), working individuals (57%) who had
some college education (40%). Sixty percent admitted to being part of a Christian
religious sect. Sixty-six percent of our participants had an overall combined annual
income that was less than $50,000.
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Table 6 Demographic Information (n=178)

Demographic Characteristics
Median Age, years (mean,standard deviation)

n (%)
30 (33, 11)

Income ($)
10,000 – 20,000
20,000 – 50,000
50,000 and greater
Race
Hispanic
Black
Caucasian
Other
Education
Grades 1-12
High School Graduate
Some College
College Graduate
Graduate School
Religion
Roman Catholic
Protestant (Christian)
Jewish
Other
Not Religious
Marital Status
Not Married
Living with partner
Married or Partnered
Divorced or Separated
Widowed
Work
Currently Working
In School
Homemaker
Unemployed
Retired
Disabled

66 (39.3)
55 (32.7)
47 (26.4)
66 (40)
28 (17)
10 (6)
61 (34)
23 (13)
32 (18)
57 (32)
39 (22)
26 (14.6)
65 (39)
43 (25)
5 (2.8)
33 (18.5)
23 (12.9)
78 (45)
34 (20)
51 (29)
9 (5)
2 (1)
100 (58)
25 (15)
14 (8)
19 (11)
4 (2)
9 (5)

Children
Have Children, mean number of kids
No Children

96 (57), 2
74 (43)
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Prior to the intervention 67% (n=124) of subjects were willing to receive the
vaccine for themselves, and 67% (n=124) indicated they would vaccinate their child if the
vaccine were free [Table 7],. Fifty-five % (n=102) agreed that the vaccine should be
required for all children, while 51% (n=95) would agree to vaccination at school.
After watching the video, individual acceptability increased to 78% (p=.0014) and
parental acceptability of free vaccination for children increased to 87 percent (p<.0001).
Support for making the vaccine mandatory and administering it in school also increased

Percentage (%) of Respondents

to 73% (p<.0001) and 65% (p<.0001) respectively. [Figure 2]
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Figure 2 Vaccine Acceptability Pre and Post Video
Intervention

Pre
Post

Individual
Acceptability

Parental
Acceptability

Support for
Mandatory
Vaccination

Support for
Vaccination in
School

Table 7 Vaccine Acceptability Pre and Post Video Intervention
Pre-Intervention Post-Intervention
(n=186)
(n=186)
Would you vaccinate yourself?
67% (124)
78% (145)
Would you make the vaccine required 55% (102)
72% (135)
for all children?
Would you vaccinate your child if it
51% (95)
65% (121)
were given at school?
Would you vaccinate your child if it
67% (124)
86% (161)
were free?

P-value
0.0014
<0.0001
<0.0001
<0.0001
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Prior to intervention, the acceptable age of vaccination was 16 years or older in 56
% of subjects. After the intervention, 82.3 % (p<.0001) of subjects were willing to accept
vaccination of children starting from age 9 and up. [Fig 3]

Figure 3 Acceptable Age of Vaccination Pre and Post
Study
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20
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Secondary analysis revealed that Hispanic, Blacks and those with combined
income less than $ 50,000 were the subgroups that were more likely to initially decline
the vaccine but after the intervention were the groups most likely to accept vaccination
for their children. [Figures 8 & 9] Of the subgroups who did not accept the vaccine and
those who changed their minds after the video, the perception that the vaccine would
promote sex did not seem to play a role in acceptability. In fact the majority of
participants (62%) did not believe the vaccine would promote sexual activity in young
people (n=114/183). Sixty-one percent (n= 113/186) of participants had children, and of
these parents 44 % (n=50/113) said they talked to their children about sex. Whether the
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participants talked to their children about sex and whether they had children did not affect
acceptability.
Table 8 Change in Acceptability by Ethnic Group
Caucasian Hispanic Black
Would you
vaccinate
your child
if the
vaccine
were free?

Group
1*
Group
2*

7

1

7

Other/No Total Fisher’s
response
Exact
Test
3
18
0.0287

6

13

22

3

Table 9 Change in Acceptability by Income Level
51K+
0-20K
21K50K
Would you
vaccinate
your child
if the
vaccine
were free?

Group
4
1*
Group 2* 20

44

No
Total
response

6

7

1

18

17

5

2

44

Fisher’s
Exact
Test
0.0723

* Group 1 = would not give vaccine even after video. Group 2 = initially said no but changed to yes post
video.

Eighty-three percent (n=154/186) of participants were able to name at least one of
the following correct answers when asked what HPV causes: genital warts, precancerous
changes (cervical dysplasia), abnormal pap smears, cervical cancer, or cancer of the
vagina. There was no significant difference between Hispanics, Blacks, and Caucasians
in their ability to answer this question correctly.
Amongst the questions answered by all participants (n=256) and not just those
completing the video, we found that the majority of participants (64%, 165/256) thought
the vaccine should be available for both men and women. Participants identified the
following as very important in their decision to get a vaccine: safety (n=234/256, 91%),
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side effects (214/256, 84%), and how long it would last (178/236, 70%). Ease of access,
number of doses, and cost followed in importance. When asked where they would go for
more information about the vaccine, 85% (n=218/256) said they would go to their doctor,
while 70% (n=178/256) cited the internet.

V. Discussion
In order to maximize the impact of the Human Papillomavirus Vaccine, policymakers will need a broad understanding of both current public acceptance and potential
barriers to vaccination. Our study found high initial individual and parental (66 and 68 %
respectively) acceptance of vaccination amongst a diverse urban sample of women aged
16 to 80.
These numbers correspond generally to high rates of acceptability found by
previous studies. Most recently (but still prior to vaccine availability), Slomovitz et al
found individual and parental acceptance rates of 77% and 67% in a population of urban
Texan women.(36) A prior study by Davis of 575 parents of 10 to 15 year olds found a
pre-education acceptance rate of 55 percent, and an earlier study in 2003 by Kahn et al of
52 female parents found even higher individual and parental acceptance (85% and 83%
respectively).(28, 37) These relatively high rates of vaccine acceptability help to mitigate
claims that the public acceptance serves as a significant barrier to vaccine delivery.
Moreover, our study suggests that public opinion can be influenced by directed education
from media sources. Use of a multi-media instrument in the form of an educational video
significantly increased overall individual and parental acceptability to 78 and 87%,
respectively. It is possible that the mixed results obtained by previous studies (26-28, 37)
on the effect of education could reflect the mode of education used; multimedia methods
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may influence acceptability more than written materials. We find it particularly
encouraging that after viewing our video, parents were significantly more willing to
vaccinate children at younger ages (age 9 and above versus age 16). Given that the
vaccine is maximally effective when administered prior to the onset of sexual activity,
vaccinating children at a younger age would improve target efficacy.
Our study suggests that public opinion of a vaccine mandate could also be
influenced by education. Although only 55% of our population initially supported
mandatory vaccination with only 51% approval of vaccination in school, following
viewing our video vaccination approval rates rose to 72% and 65% respectively.
Although this is true, the lowest rate of acceptability was found with in school
vaccination, which may indicate that this is something the public may not be ready for.
As for the concern that the vaccine could promote sexual activity, a great deal of
research supports the claim that sex education and condom distribution do not lead to an
increase in sexual activity. Studies have shown that comprehensive sex education
actually reduces the frequency of sex, delays initiation of sexual intercourse and reduces
the number of sexual partners. [18-20]. Over half (62%) of all participants in this study
did not believe the HPV vaccine would lead to increased sexual activity among
recipients. In light of the fact that a great deal of media attention has been devoted to
claims that the vaccine could encourage sexual activity in teens, the fact that the majority
of our study population did not feel this to be the case is encouraging.
The question of cost still seems to be an important one within the HPV
vaccination debate. Who will pay for the mandated vaccine? Policy makers have not
answered the question if consumers, insurers, federal agencies, or states will bear the
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cost. Our study revealed that the greatest change and increase in acceptance for
vaccination for children in the context of free vaccination. Though individuals did not
rank cost very highly amongst factors that would influence their willingness to receive a
vaccine (safety, side effects, and duration of protection were most important), it no doubt
plays a role. Finding a way to address cost issues will be important to help ensure broad
spectrum access.
Aggressive marketing campaigns by Merck for Gardasil nationwide have no
doubt played a role in increasing public knowledge and awareness of the need for HPV
vaccination. The positive ramifications of this are evident in our study, as 81 percent of
the study population was able to name correctly at least one sequelae of HPV infection. A
review of media representation of HPV by Calloway et al found that ads were not always
specific in clearly explaining the connections between HPV and Cervical Cancer. [15] It
is for this reason that we advocate the development of other media tools to educate about
HPV and ensure that women understand the links between HPV, abnormal Pap smears,
genital warts, and cervical cancer.
Our educational intervention also demonstrated that lower income, minority
populations may be the best target population to affect change in attitudes towards the
HPV vaccine using this educational tool. Our experience revealed that utilization of
video as a way to educate helped keep the individual focused and interested in the
material and addressed misunderstandings of information presented by use of visual aids.
This may be more effective in subgroups where public-based health clinics service lower
income or less educated populations.
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Our data showed that a novel approach of educational intervention by video improved
rates of parental vaccine acceptability, in a minority, predominantly underserved
population. Nevertheless, this study may have been influenced by several factors,
including selection bias whereby the majority of participants were solicited from a
gynecology and gyn-specific colposcopy clinic. These subjects may have been sensitized
to the impact of HPV and the possible influence of the HPV vaccine, more than a
population solicited in a different community setting. Although the participation rate was
relatively high at 73%, they may also have been more inclined to participate within the
setting of a gynecology clinic than at a local community site. These results may not be
directly applicable to the general population.
Furthermore, since all subjects were female, the knowledge and acceptance rate of
males of this same topic remains unknown. We cannot speculate on whether fathers
would be as knowledgeable or inclined to support vaccination of their daughters.
Additionally, we have not tested whether other intervention methods such as books,
pamphlets, posters, or acoustic means such as through radio-ads would be as affective.
Although our video did show a significant increase in parental vaccine acceptability after
viewing, this intervention method may not be entirely practical or feasible in all settings.
We also do not know if large scale application of our video intervention would produce
the same effect as that viewed intimately on a laptop or within a small group setting as
was done in this study.
In order to determine the full utility of a video intervention to increase
acceptability of the HPV vaccine, a larger study targeted to both women and men of a
variety of ages, of racial and social backgrounds, and from a variety of community
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settings may help us answer the questions posed above. In this manner, we may better
identify and target the populations most vulnerable to developing cervical dysplasia and
cancer.
The HPV vaccine represents a rare public health opportunity to protect a large
cohort of individuals from a devastating illness, not to mention the psychological and
economic tolls of screening practices. Achieving target levels of vaccination will require
sophisticated programs to counter barriers such as cost, access, and individual
acceptance. Our study suggests that education, in this case through multimedia, can have
a powerful effect on the latter. Thus, by utilizing this information to develop appropriate
educational tools, we can directly impact rates of cervical dysplasia, genital warts, and
cervical cancer in the near and distant future.
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Appendix I. Sample Survey
1. Please Circle:

MALE

FEMALE

2. I have heard of a virus called Human Papillomavirus (HPV).

Please circle:
Yes No Not Sure
Yes
No
I don’t know

3. Can you be tested for Human Papilloma Virus (HPV)?

4. What does HPV cause? (Circle all that you think apply)
Genital Warts

Infertility (cannot have children)

Herpes

Premature Birth

Precancerous Changes
(Cervical Dysplasia)

Abnormal PAP smears
AIDS

Cervical Cancer
Cancer of the Vagina
I Don’t Know
5. Do you know what a Pap smear tests for?

Yes
No
Not Sure

6. ONLY ANSWER IF YOU SAID YES TO
QUESTION 4: what does a Pap smear check for?
Mark all that might apply.

Chlamydia or Gonorrhea
Pre-Cancerous Cells
Cervical Cancer
Fertility
Yeast Infections
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7. How is HPV spread from one person to another? (Circle all that you think apply)
Kissing

Anal Sex

Close skin contact without
sexual intercourse

Sexual Intercourse
Sitting on public toilets

Oral Sex
From someone’s cough
I Don’t Know

8. Condoms prevent spread of HPV.

Always
Sometimes
Never
I don’t know

9. Taking the birth control pill prevents you from getting
infected with HPV.

Yes
No
I don’t know

10. Have you ever had a sexually transmitted disease?

Yes
No
Not Sure

11. FOR WOMEN ONLY: Have you ever been told you had
an abnormal Pap smear and/or precancerous change?

Yes
No
I don’t know

12. FOR WOMEN ONLY: Have you had cervical cancer?

Yes
No

13. Have you or any of your family members had cancer?

Yes
No
I don’t know.

14. Have you talked to your child about sex?

Yes
No
Don’t have kids
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15. Who talks to your children about sex? (mark all that apply)
Myself

Other youth activity
programs

Child’s School
Church group or religious
leader

Media (TV or radio or
internet)

Child’s Doctor
My kids are too
young to talk about sex
Other:
__________________

16. If you have not talked to your children about sex, why not?
My child is too young.
Someone else has talked
to them already.

I am not comfortable
talking to them about sex.

My child will not
listen to me

I have no time to talk
to them about sex.

Other:
__________________

My child’s school will talk
to them.

17. I knew before today that there is an HPV vaccine.

Yes
No
I’m not sure

18. Who do you think the vaccine should be for?

Women only
Men only
Women and Men
Should not be
available.

19. What is the youngest age you would give your child the
vaccine?

9
10-12
13-15
16-18
Older than 18
Not Sure
I would not give
my child the vaccine.

20. Would you vaccinate your child if the vaccine is free?

Yes
No
I’m not sure
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21. Would you vaccinate your child if the vaccine were
given at school?

Yes
No
I’m not sure

22. If your doctor recommends the HPV vaccine would you
give it to your child?

Yes
No
I’m not sure

23. Would you support making the HPV vaccine required
for all children?

Yes
No
I’m not sure

24. Do you think giving young people the HPV vaccine will
make them more likely to have sex?

Yes
No
I’m not sure

25. How would you describe the HPV vaccine to your child? Mark all that apply.
It prevents cervical cancer.
It prevents a sexually
transmitted disease.

All girls get the
vaccine.
It prevents women’s
diseases,

Not sure
Other:
__________________

26. If you answered “not sure” to questions 17-23, is it because you don’t know
enough about the HPV vaccine?
Yes

No

Other reason (please explain: _______________________

_____________________________________________________________________
_____________________________________________________________________

27. (FOR MEN AND WOMEN BOTH) Would you
get the vaccine yourself?

Yes
No
I am not sure

28. Would you get the vaccine to protect your
partner(s)?

Yes
No
I am not sure

29. If your doctor recommends the HPV vaccine
would get it?

Yes
No
I am not sure
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30. Would your partner (husband, wife, boyfriend or
girlfriend) support your decision to get the HPV
vaccine?

Yes
No
I am not sure

31. How important are the following items when you think about getting a
vaccine?
Very Important

Neutral

Not Important

Safety
How Easy it Would be to Get It
Side Effects
Number of Doses I Would Need
Cost
How Long it Lasts
32. Where would you go to find out more about the HPV vaccine? (Mark all that
apply)
Radio

Friend

Church group

Internet

Community Group

Doctor

Television
Library

Other people of the same
race only.
School Staff
Other extended family
members

Child’s doctor
(pediatrician)
Other family members
I would not look for any
more information.

Other: _____________________________________________________________

After learning more about HPV, please answer questions below:

1. Who do you think the vaccine should be
for?

Girls only
Boys only
Boys and Girls
Should not be available.

37
9
10-12
13-15
2. What is the youngest age you would give your child
16-18
the vaccine?
Older than 18
Not Sure
I would not give my child
the vaccine.

3. Would you vaccinate your child if the vaccine
is free?

Yes
No
I’m not sure

4. Would you vaccinate your child if the vaccine
is given at school?

Yes
No
I’m not sure

5. Would you support making the vaccine required
for all children?

Yes
No
I’m not sure

6. If your doctor recommends the HPV vaccine would
you give it to your child?

Yes
No
I’m not sure

7. Do you think giving young people the HPV vaccine
will make them more likely to have sex?

Yes
No
I’m not sure

8. How would you describe the HPV vaccine to your child? Mark all that apply.
It prevents cervical cancer.
It prevents a sexually
transmitted disease.

All girls get the
vaccine.
It prevents women’s
diseases,

Not sure
Other:
__________________

9. Would you get the vaccine yourself?

Yes
No
I am not sure

10. Would you get the vaccine to protect your
partner(s)?

Yes
No
I am not sure
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11. How important are the following items when you think about getting a
vaccine?
Very
Important

Neutral

Not Important

Safety
How Easy it Would be to Get It
Side Effects
Number of Doses I Would
Need
Cost
How Long it Lasts
Demographics (Information for survey purposes only)
1. What is your age? _________________
2. Please circle: Female

Male

Not married
Living with partner but not married
Currently married or partnered
Divorced or legally separated
Widowed

3. What is your marital status?

4. What is your ethnic background?
Latina or Hispanic:
Cuban

Caribbean/West
Indian:

European:
Irish

Dominican

Haitian

Italian

Puerto Rican

Jamaican

Russian

Central American

Trinidadian

South American
Mexican
Other: ________
African American
Native American
Native Hawaiian
Other Ethnic Group:

____________________

Other:
___________________
Asian:
Vietnamese
Cambodian
Laotian
Chinese
Japanese
Indian
Other:
___________

Other:
___________
Jewish
Middle Eastern
African:
Somalian
Nigerian
Senegalese
Cape Verdean
Other:
___________
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5. What is your zip code?

6. What is your highest level of education?

No formal school
Grades 1-12 (primary)
High school graduate (secondary)
Some college
College graduate
Graduate School
Vocational/ Tech school

7. Which of the following best describes your
work?

Currently Working
In School (Student)
Homemaker (housewife)
Unemployed (not working)
Retired
Extended Sick Leave
Disabled
Other: _____________________

8. If you are currently working, what do you do?
Retail Store Clerk
Healthcare Support
(Home Health Aid, Nurse’s
Aid, Medical Assistant)
Protective Services
(Firefighter, Police Officer)
Food Preparation &
Serving (cook, fast food
restaurant work).

Management
Business and Financial
Computer and
Mathematical

Education,
Training & Library
Arts, Design,

Architecture and

Engineering
Life, Physical, &
Social Science

Building, Grounds
Cleaning, & Maintenance

Community &
Social Services

Legal Occupations

Media, Sports &
Entertainment
Healthcare
Practitioners and
Technical Work
Other
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8. What is your total annual household
income?

9. (WOMEN ONLY) Where do you get your
Pap test?

10. What type of heath insurance do you
currently have?

Less than $10,000
$10,000 to $20,000
$21,000 to $30,000
$31,000 to $50,000
$51,000 to $100,000
Over $100,000
I don’t know what a Pap test is.
Primary Care Doctor
Ob-Gyn
I don’t get Pap tests.
Pediatrician
Other___________________
Medicare
Medicaid or Mass Health?
Private Insurance through my
work or my spouse’s work.
Get free care.
I do not have health insurance.

11. What is your religion?

Roman Catholic
Jewish
Protestant (Christian)
Muslim
Not Religious
Other: _____________________

12. How much does your faith, religion affect
your decisions about health?

Not at all
Somewhat (a little)
Most of the time
Affects all my health decisions

13. Do you have children?
Yes
No 14. How many children do you have?
If yes, please answer questions 14 and 15.
__________
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15. Please list your children by age and if they are a girl or boy.
Age

Girl

Boy

1.
2.
3.
4.
5.
6.
7.
8.

15. I give my children all the vaccines
recommended by their doctor.

Yes

No

Sometimes
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